| Autor: |
Deeb D; Department of Surgery, Henry Ford Health System, Detroit, MI 48202, USA., Gao X; Department of Surgery, Henry Ford Health System, Detroit, MI 48202, USA., Liu Y; Department of Surgery, Henry Ford Health System, Detroit, MI 48202, USA., Pindolia K; Department of Research, Henry Ford Health System, Detroit, MI 48202, USA., Gautam SC; Department of Surgery, Henry Ford Health System, Detroit, MI 48202, USA. |
| Abstrakt: |
Pristimerin (PM) is a promising anticancer agent that has exhibited strong antiproliferative and apoptosis-inducing activity in various types of cancer cells. In the present study, we investigated the role of telomerase in mediating the antitumor activity of PM in pancreatic ductal adenocarcinoma (PDA) cells. PM inhibited cell proliferation, arrested cells in the G1 cell cycle phase and induced apoptosis in MiaPaCa-2 and Panc-1 PDA cells. These antitumor activities of PM correlated well with the inhibition of human telomerase reverse transcriptase (hTERT), the gene that codes for the catalytic subunit of telomerase complex. Gene knockin and knockdown approaches demonstrated that hTERT regulates the response of PDA cells to PM. PM inhibited hTERT expression by suppressing the transcription factors Sp1, c-Myc and NF-κB which control hTERT gene expression. PM also inhibited protein kinase Akt, which phosphorylates and facilitates hTERT nuclear importation and its telomerase activity. These findings identified hTERT (telomerase) as a potential therapeutic target of PM for the treatment of PDA. |
